SCHEMBL918858

SCHEMBL918858

CCCCCCCCCC(O)C(O)CO

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.65
CYP2D6 P10635 2/20 0.65
SPHK1 Q9NYA1 2/20 0.65
GMNN O75496 1/20 0.65
POLB P06746 1/20 0.65
THPO P40225 1/20 0.65
MTOR P42345 1/20 0.65
BLM P54132 1/20 0.65
KDM4E B2RXH2 1/20 0.65
TP53 P04637 1/20 0.65
CYP1A2 P05177 1/20 0.65
CYP3A4 P08684 1/20 0.65
MAPT P10636 1/20 0.65
CETP P11597 1/20 0.65
HTT P42858 1/20 0.65
UBE2N P61088 1/20 0.65
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
ASAH1 Q13510 1/20 0.49
GPR84 Q9NQS5 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3796385 1.00 LMNA (0.65) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL1964586 1.00 LMNA (0.65) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL4287325 1.00 LMNA (0.65) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL313894 1.00 LMNA (0.65) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL2312898 1.00 LMNA (0.65) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL10571108 1.00 LMNA (0.65) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL25243382 1.00 LMNA (0.65) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL2233834 1.00 LMNA (0.65) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL1964037 1.00 LMNA (0.65) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL918041 1.00 LMNA (0.65) LMNACYP2D6SPHK1GMNNPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8889890-B2 Ketal esters of oxocarboxylic acids and process of making SEGETIS, INC. (US) 2014-11-18 US claimed
US-20120323024-A1 KETAL ESTERS OF OXOCARBOXYLIC ACIDS AND PROCESS OF MAKING SEGETIS, INC. (US) 2012-12-20 US claimed
WO-2011032095-A1 KETAL ESTERS OF OXOCARBOXYLIC ACIDS AND PROCESS OF MAKING SEGETIS, INC. (US) 2011-03-17 WO claimed
US-5446033-A Antitumor agent; storage stability, antiseptic, chemical resistance, by-product inhibition ASTA MEDICA AG (DE) 1995-08-29 US claimed
EP-0248858-B1 NOVEL PHOSPHO-COMPOUNDS AND MEDICAMENTS CONTAINING THESE Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 1990-02-28 EP claimed
EP-0248858-A1 NOVEL PHOSPHO-COMPOUNDS AND MEDICAMENTS CONTAINING THESE. MAX PLANCK GESELLSCHAFT (DE) 1987-12-16 EP claimed
WO-1987003596-A2 NOVEL PHOSPHO-COMPOUNDS AND MEDICAMENTS CONTAINING THESE MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSC (DE) 1987-06-18 WO claimed
EP-0224925-A2 Phosphorous compounds and medicines containing them Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 1987-06-10 EP claimed
US-20250368983-A1 CONTROLLING FOR TAGMENTATION SEQUENCING LIBRARY INSERT SIZE USING ARCHAEAL HISTONE-LIKE PROTEINS KAPA BIOSYSTEMS INC (US) 2025-12-04 US disclosed
EP-4581153-A1 IMPROVEMENTS TO NEXT-GENERATION TARGET ENRICHMENT PERFORMANCE F. Hoffmann-La Roche AG (CH) 2025-07-09 EP disclosed
EP-4547839-A1 CONTROLLING FOR TAGMENTATION SEQUENCING LIBRARY INSERT SIZE USING ARCHAEAL HISTONE-LIKE PROTEINS Kapa Biosystems, Inc. (US) 2025-05-07 EP disclosed
CN-119895049-A Improvements to next generation target enrichment performance 豪夫迈·罗氏有限公司 2025-04-25 CN disclosed
CN-119497755-A Control of library insert size for fragmentation and tag sequencing using archaebacteria histone-like proteins 卡帕生物系统公司 2025-02-21 CN disclosed
WO-2024046992-A1 IMPROVEMENTS TO NEXT-GENERATION TARGET ENRICHMENT PERFORMANCE F. HOFFMANN-LA ROCHE AG (CH) 2024-03-07 WO disclosed
EP-0230575-A2 Medicament active against tumours, containing hexadecylphosphocholine Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 1987-08-05 EP disclosed
WO-1987003480-A2 MEDICAMENT WITH ANTI-TUMORAL ACTION CONTAINING HEXADECYLPHOSPHOCHOLINE MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSC (DE) 1987-06-18 WO disclosed
WO-1987003596-A2 NOVEL PHOSPHO-COMPOUNDS AND MEDICAMENTS CONTAINING THESE MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSC (DE) 1987-06-18 WO disclosed
EP-0225608-A2 Medicine Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 1987-06-16 EP disclosed
EP-0224925-A2 Phosphorous compounds and medicines containing them Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 1987-06-10 EP disclosed
US-4101589-A SURFACTANTS, LUBRICANTS, URETHANES, ALKYD RESINS PILOT CHEMICAL COMPANY (US) 1978-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120323024-A1 KETAL ESTERS OF OXOCARBOXYLIC ACIDS AND PROCESS OF MAKING AKR1C3, OXER1, ACSL6 LMNA 2114/4885CYP2D6 99/4885SPHK1 309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.